Rxivist combines preprints from bioRxiv with data from Twitter to help you find the papers being discussed in your field. Currently indexing 70,242 bioRxiv papers from 306,709 authors.
Cis-Compound Mutations are Prevalent in Triple Negative Breast Cancer and Can Drive Tumor Progression
Michael O Dorschner,
Colin C Pritchard,
Kimberly A. Burton,
Elisabeth M. Mahen,
Francis M. Senecal,
Wayne L. Monsky,
Stephen C. Schmechel,
Stephen K. Allison,
Vijayakrishna K. Gadi,
Sophie R. Salama,
Amie J. Radenbaugh,
Jill M Johnsen,
Steven C. Benz,
Walter L. Ruzzo,
William S Noble,
C. Anthony Blau
Posted 05 Nov 2016
bioRxiv DOI: 10.1101/085316
Posted 05 Nov 2016
About 16% of breast cancers fall into a clinically aggressive category designated triple negative (TNBC) due to a lack of ERBB2, estrogen receptor and progesterone receptor expression1-3. The mutational spectrum of TNBC has been characterized as part of The Cancer Genome Atlas (TCGA)4; however, snapshots of primary tumors cannot reveal the mechanisms by which TNBCs progress and spread. To address this limitation we initiated the Intensive Trial of OMics in Cancer (ITOMIC)-001, in which patients with metastatic TNBC undergo multiple biopsies over space and time5. Whole exome sequencing (WES) of 67 samples from 11 patients identified 426 genes containing multiple distinct single nucleotide variants (SNVs) within the same sample, instances we term Multiple SNVs affecting the Same Gene and Sample (MSSGS). We find that >90% of MSSGS result from cis-compound mutations (in which both SNVs affect the same allele), that MSSGS comprised of SNVs affecting adjacent nucleotides arise from single mutational events, and that most other MSSGS result from the sequential acquisition of SNVs. Some MSSGS drive cancer progression, as exemplified by a TNBC driven by FGFR2(S252W;Y375C). MSSGS are more prevalent in TNBC than other breast cancer subtypes and occur at higher-than-expected frequencies across TNBC samples within TCGA. MSSGS may denote genes that play as yet unrecognized roles in cancer progression.
- Downloaded 798 times
- Download rankings, all-time:
- Site-wide: 11,722 out of 70,260
- In clinical trials: 19 out of 99
- Year to date:
- Site-wide: 15,149 out of 70,260
- Since beginning of last month:
- Site-wide: 9,390 out of 70,260
Downloads over time
Distribution of downloads per paper, site-wide
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!